ERBB2 and breast cancer: However, no association was observed between CDK2 with p53 co-expression and the outcome in either endocrine-therapy-naïve (Supplementary Figure S2C) or triple-negative (Supplementary Figure S2D) or HER2-enriched BC (Supplementary Figure S2E) patients.